January 17, 2017 07:23 AM EST
R&D

Al­co­bra blast­ed by a PhI­II flop for AD­HD drug as its op­tions dwin­dle

John Carroll

Editor & Founder

You can turn out the lights at Al­co­bra. The par­ty is over, and it end­ed bad­ly.

This morn­ing the Is­raeli biotech $AD­HD re­vealed that its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Ex­clu­sive: British start­up rais­es $16M to find genes that rewind the epi­ge­net­ic clock

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times